Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Levobupivacaine
Homo sapiens
Drug Action Pathway
Levobupivacaine is an anaesthetic most commonly used for nerve block, it belonds to the pipecoloxylidide family. It is an enantiomer of bupivacaine, capable of less vasodilation and longer duration of action. Adverse effects only are anticipated if levobupivacaine is administered incorrectly, which leads to systemic exposure and toxicity due to overexposure. Levobupivacaine acts as an anaesthetic through blocking nerve impulse generation and conduction, by reducing the rate of action potential through binding of the intracellular portion of sodium channels and blocks the sodium influx into nerve cells. Levobupivacaine is metabolized by CYP3A4 and CYP1A2 into desbutyl levobupivacaine and 3-hydroxy levobupivacaine. 3-hydroxy levobupivacaine is capable of being further metabolized to glucuronide and sulfate conjugates.
References
Levobupivacaine References
Foster RH, Markham A: Levobupivacaine: a review of its pharmacology and use as a local anaesthetic. Drugs. 2000 Mar;59(3):551-79. doi: 10.2165/00003495-200059030-00013.
Pubmed: 10776835
McClellan KJ, Spencer CM: Levobupivacaine. Drugs. 1998 Sep;56(3):355-62; discussion 363-4. doi: 10.2165/00003495-199856030-00005.
Pubmed: 9777312
Sanford M, Keating GM: Levobupivacaine: a review of its use in regional anaesthesia and pain management. Drugs. 2010 Apr 16;70(6):761-91. doi: 10.2165/11203250-000000000-00000.
Pubmed: 20394458
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Settings